Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus intensive chemotherapy for previously untreated FLT3-ITD acute myeloid leukemia
ACTRN12611001112954Phase 2Completed
- Sponsor
- Leukaemia Foundation
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Sorafenib + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: 2-year event-free survival. Started Jan 2013; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12611001112954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001112954.